Curis Inc (CRIS)vsModerna Inc (MRNA)
CRIS
Curis Inc
$0.83
-5.62%
HEALTHCARE · Cap: $2.01M
MRNA
Moderna Inc
$198.88
+2.08%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 51546% more annual revenue ($2.23B vs $4.31M). CRIS leads profitability with a 0.0% profit margin vs -141.4%. CRIS earns a higher WallStSmart Score of 34/100 (F).
CRIS
Avoid34
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+80.8%
Fair Value
$5.53
Current Price
$0.83
$4.70 discount
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$198.88
$64.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -166.6% — below average capital efficiency
Trading at 11.7x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRIS
The strongest argument for CRIS centers on P/E Ratio, Price/Book, Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CRIS
The primary concerns for CRIS are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CRIS profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
CRIS carries more volatility with a beta of 3.00 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
CRIS generates stronger free cash flow (-10M), providing more financial flexibility.
Bottom Line
CRIS scores higher overall (34/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Curis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?